Lytix Biopharma AS (LYTIX.OL)
- Previous Close
5.36 - Open
5.44 - Bid 5.00 x --
- Ask 5.60 x --
- Day's Range
5.44 - 5.60 - 52 Week Range
4.55 - 15.00 - Volume
34,012 - Avg. Volume
55,750 - Market Cap (intraday)
382.267M - Beta (5Y Monthly) -0.60
- PE Ratio (TTM)
-- - EPS (TTM)
-1.74 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
14.00
Lytix Biopharma AS, a clinical stage biotech company, develops novel cancer immunotherapies for cancer therapy in the United States. Its lead product candidate is LTX-315, an oncolytic molecule that is developed for intratumoral injections, which is in Phase II clinical trials, to treat melanoma, basal cell carcinoma, and advanced soft tissue sarcoma. The company also offers LTX-401, an oncolytic molecule in preclinical phase for the treatment of deep-seated tumors, such as hepatocellular carcinoma in liver cancer and liver metastases. It has a partnership with Verrica Pharmaceuticals Inc. for the development and commercialization of LTX-315 for the treatment of all malignant and pre-malignant dermatological indications. Lytix Biopharma AS was founded in 2003 and is based in Oslo, Norway.
www.lytixbiopharma.comRecent News: LYTIX.OL
View MorePerformance Overview: LYTIX.OL
Trailing total returns as of 5/9/2025, which may include dividends or other distributions. Benchmark is OBX Total Return Index (OBX.OL) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: LYTIX.OL
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: LYTIX.OL
View MoreValuation Measures
Market Cap
382.27M
Enterprise Value
255.60M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
27.22
Price/Book (mrq)
3.54
Enterprise Value/Revenue
22.96
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-56.97%
Return on Equity (ttm)
-118.41%
Revenue (ttm)
11.13M
Net Income Avi to Common (ttm)
-94.27M
Diluted EPS (ttm)
-1.74
Balance Sheet and Cash Flow
Total Cash (mrq)
130.79M
Total Debt/Equity (mrq)
2.45%
Levered Free Cash Flow (ttm)
-34.62M